sameAs
Interventions for lowering plasma homocysteine levels in kidney transplant recipientsInsulin and glucose-lowering agents for treating people with diabetes and chronic kidney diseaseInterventions for preventing intradialytic hypotension in haemodialysis patientsHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisAntiplatelet agents for chronic kidney diseaseHMG CoA reductase inhibitors (statins) for dialysis patientsAntioxidants for chronic kidney diseaseInterventions for erythropoietin-resistant anaemia in dialysis patientsAntiplatelet agents for chronic kidney diseaseHMG CoA reductase inhibitors (statins) for kidney transplant recipientsHaemodialysis duration, frequency and intensity for end-stage kidney diseaseGlucose lowering therapies for chronic kidney disease and kidney transplantationAntihypertensive agents for preventing diabetic kidney diseaseAnticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney diseaseAntiplatelet agents for chronic kidney diseaseInterventions for preventing intradialytic hypotension in haemodialysis patientsHMG CoA reductase inhibitors (statins) for dialysis patientsInterventions for lowering plasma homocysteine levels in dialysis patientsInterventions for lowering plasma homocysteine levels in kidney transplant recipientsHMG CoA reductase inhibitors (statins) for kidney transplant recipientsAntioxidants for chronic kidney diseaseHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisHMG CoA reductase inhibitors (statins) for dialysis patientsInterventions for erythropoietin-resistant anaemia in dialysis patientsHMG CoA reductase inhibitors (statins) for kidney transplant recipientsAntihypertensive agents for preventing diabetic kidney diseaseThe effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysisInterventions for lowering plasma homocysteine levels in dialysis patientsEffects of fibrates in kidney disease: a systematic review and meta-analysisThe endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathyEffects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysisEffects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trialsKidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study.Sirolimus: a single center experience in combination with calcineurin inhibitors.The relationship between proteinuria and coronary risk: a systematic review and meta-analysisEffect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trialsIntensities of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis.Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.Long-term cancer risk of immunosuppressive regimens after kidney transplantation.
P50
Q24188051-C9673B1E-BDAC-459F-9877-2EB4A1A950E4Q24188192-CA84DA5F-008E-4A41-B855-EF003B4047A7Q24192974-68E56DDF-C60D-4186-87EA-E3DD54C18008Q24194514-3CC4107B-D9C8-4E7D-9146-D74AE4F3D8E8Q24197614-CCB0311A-666A-4AEB-BCDE-68D70E529922Q24198108-A3BDDD15-D605-4004-BA7D-253E44650D65Q24198197-3DC297F7-1AE2-41F9-A04A-0CF24E925B21Q24200248-349C57DC-7E09-4BD5-8FAE-F8BF42F6EECFQ24200752-CB649E79-DA06-425F-B0B6-6E5B66277980Q24200984-22BA2B6E-8801-40DE-915B-17CB57AD6203Q24201109-C9843AC2-ABAE-47DB-B3CF-69E6B7E2B40EQ24201814-DCB53D88-D952-4EA2-BDFD-DD734B99098CQ24202090-CEE5CEE4-85F7-485F-B192-91969E67F4AFQ24203776-C07BC3C0-60AB-42C5-BF83-5F1F15F5CD17Q24234115-58CE5669-0461-4E21-A0FF-470D4AF5432EQ24234733-DA8E9ED5-F826-4D3F-949F-9903642C5060Q24239881-842DF004-51E6-45F4-BE0D-0EA354235701Q24240554-E7BDDDE1-D331-46CC-8412-192F4F56EFD6Q24240632-566403E7-9D44-45FA-B920-29B9BDB1C29AQ24241098-4D1B6DEC-7432-44B1-9D9A-D02A2B7F329BQ24241102-ED7D1EC9-0B54-4976-A990-7B164C9C7C9BQ24241472-4F825BD4-DB06-46E5-8B7E-BBAD66D8032BQ24241531-F811BDAD-5225-4899-A08E-5958A429638BQ24241704-E4108580-0300-445F-9CBD-920671FBF1ACQ24242586-D497C5C0-5E22-41CA-871B-95E229FE879FQ24245557-B3D8F37E-4690-4975-B9F2-AF74982607AEQ24604736-7198F497-C34E-49CC-B48A-0D1DC387456AQ26471859-9741CF2F-8397-48B7-B2E5-F1E6FBC8DF8FQ27008473-7109FDE8-CA5C-474A-B46D-427BABC2C5E2Q28237978-CDA1DAFA-97EF-4EFE-9C78-8DCFC8C74CE7Q28482437-08B047DC-C88D-4A15-AFDF-9619F4750769Q30841365-DECA5055-CD15-4AB7-A819-58C1AFACD2DAQ30948705-940DDEAF-18D7-4FCD-AC63-C9EA6DBC3FCFQ31126016-52E83B6D-7E54-4028-9976-E7A893058246Q33347963-FFBE7518-5CE2-46F2-B1EF-FCE903C7999CQ33378672-4E252A28-5367-43C5-AC88-97ED80C6D52CQ33413288-F140FBAF-AA67-41DB-81C3-EAEBE79DE996Q33556332-8ACC2E56-4D2D-4E97-BA9D-8296E00FBFC7Q33576435-419656A2-7352-4B60-940A-3EDE25279F1EQ33834315-EE55BC04-EAC0-4F3A-8156-2EECDB9C46C9
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vlado Perkovic
@ast
Vlado Perkovic
@en
Vlado Perkovic
@es
Vlado Perkovic
@nl
Vlado Perkovic
@sl
type
label
Vlado Perkovic
@ast
Vlado Perkovic
@en
Vlado Perkovic
@es
Vlado Perkovic
@nl
Vlado Perkovic
@sl
prefLabel
Vlado Perkovic
@ast
Vlado Perkovic
@en
Vlado Perkovic
@es
Vlado Perkovic
@nl
Vlado Perkovic
@sl
P106
P1153
22135866300
P21
P31
P496
0000-0002-4257-7620
P551
P569
1969-03-08T00:00:00Z
2000-01-01T00:00:00Z